Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Protea Opens Training Center

By Drug Discovery Trends Editor | June 19, 2012

Protea Biosciences Group Inc., a leading developer of technologies and services for biomolecular analysis, announced the opening of a dedicated customer demonstration and training center for its LAESI (laser ablation electrospray ionization) DP-1000 system. The facility, located in the Company’s headquarters in Morgantown, West Virginia, uses state-of-the-art mass spectrometers that interface with Protea’s proprietary LAESI DP-1000 system.

“We are excited to provide potential customers with the opportunity to interact first-hand with our LAESI DP-1000 system,” said Alessandro Baldi, Protea’s Vice President and General Manager. “This dedicated facility will allow interested scientists to train on the LAESI DP-1000 and use the system to analyze their samples, allowing them to gain familiarity with the platform and its many applications. The opening of our demonstration and training center follows the successful launch of our Bioanalytical Services laboratory, a 10,000 square foot facility dedicated to conducting bioanalytical projects for biopharmaceutical companies. These two facilities illustrate our commitment to fulfilling our customers’ needs by supplying both products and services, giving them the ability to determine which Protea solution better enhances their research.”

Highlighting expanded applications of Protea’s LAESI technology, several posters featuring LAESI were presented at the 60th Annual American Society for Mass Spectrometry (ASMS) Conference in May.

“For the first time, we presented applications of in vivo mass spectrometry, profiling metabolites directly from cell cultures or bacteria colonies at ambient pressure, with no sample preparation. When profiling a living entity, this means metabolites can be mapped over time, adding an entirely new and valuable dimension to biological research,” Baldi continued.

The posters presented at ASMS 2012 detailed research done by scientists at Protea, as well as esteemed collaborators from prestigious research institutions such as Ohio University, West Virginia University, and FOM Institute AMOLF in Amsterdam. Each of the independent studies highlighted the advantages provided by LAESI DP-1000 over traditional sample methods for mass spectrometry, including its minimal sample preparation, wide range of sample types, 2D & 3D mapping, and high throughput. In these studies the LAESI DP-1000 direct ionization system was interfaced with multiple mass spectrometry platforms, demonstrating its broad commercial potential to enter laboratories worldwide.

Date: June 12, 2012
Source: Protea Biosciences Group Inc. https://proteabio.com/


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50